October 13, 2022

Essex Biotechnology Secures Exclusive Rights in Mitotech’s lead candidate SkQ1 for Ophthalmology

February 24, 2022

Mitotech CSO to present at Mitochondria-Targeted Drug Development Summit

January 26, 2022

Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease

December 15, 2021

Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON

May 6, 2021

Mitotech's focus on opthalmology discussed in Fierce Biotech publication

March 4, 2021

Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021

February 26, 2021

Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease

February 1, 2021

Mitotech to present at LSX Congress 2021

January 11, 2021

Mitotech S.A. To Present at Biotech Showcase Digital 2021 Conference

October 23, 2020

Mitotech to present in Eyecelerator's Retina Livestream organized by AAO and ASCRS

August 25, 2020

Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

December 12, 2019

Mitotech and Essex Bio-Technology Announce Enrollment in VISTA-2 - a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

October 29, 2018

Mitotech Completes First Patient Visit in VISTA-1 - Phase 2b/3 Clinical Study of SkQ1 for Dry Eye Disease

October 23, 2018

Mitotech Initiates Phase 2b/3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology

July 19, 2018

Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease

October 24, 2017

Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action

April 26, 2017

Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients

April 20, 2017

Mitotech's SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication

March 21, 2017

Mitotech's lead compound significantly increased lifespan of rapidly aging mice

February 10, 2017

Mitotech discusses SkQ1 and Dry Eye Disease in a recent Fierce Biotech article

February 7, 2017

Mitotech will attend the Biotech and Money conference in London, Feb 7-8, 2017

January 20, 2017

Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations

September 9, 2016

Mitotech S.A. is granted a patent in anti-aging

July 27, 2016

Mitotech S.A. announces its Ophthalmic Scientific Advisory Board

March 20, 2016

Oxidative stress and dry eye in Review of Ophthalmology

March 1, 2016

Mitotech S.A. to present at ARVO 2016

February 5, 2016

Mitotech CEO to present at the annual BIO CEO and Investor Conference 2016

January 25, 2016

Mitotech S.A. to initiate its first clinical study of a systemic formulation of SkQ1

January 10, 2016

Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal

December 27, 2015

Results of Mitotech's Multicenter Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal

October 16, 2015

Mitotech S.A. to present at the 2015 Sofinnova Japan Biopharma Partnering Conference

May 3, 2015

Mitotech's posters at ARVO 2015 in Denver, May 3-7

April 23, 2015

Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome

April 21, 2014

Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment

May 14, 2013

Mitotech completes series of uveitis studies

December 9, 2012

Mitotech's posters at ARVO 2015 in Denver, May 3-7

January 17, 2012

Mitotech initiated pre-clinical program for SkQ1 compound in the U.S.